Table 1.
Clinical characteristics of prostate cancer patients.
| Clinical Parameter | Low Risk (LR) | Intermediate Risk (IR) | High Risk (HR) | Metastasis (M1) |
|---|---|---|---|---|
| Number of patients | 15 | 32 | 42 | 30 |
| Age at first sample, median (quartiles) years | 66 (59–69) | 68 (62–72) | 70 (67–73) | 67 (63–79) |
| Initial PSA, median (quartiles) µg/L | 6.2 (4.7–6.8) | 5.3 (4.3–9.5) | 28.5 (21–51) | 193 (98–372) |
| Risk group * | ||||
| 1: T 1–2 and GS < 7 and PSA < 10 µg/L | 15 | |||
| 2: T 1–2 and/or GS 7 and/or 10 ≤ PSA < 20 µg/L | 32 | |||
| 3a: T 1–2 and/or GS 8–10 and/or 20 ≤ PSA < 50 µg/L | 17 | |||
| 3b: T 3 and/or PSA < 50 µg/L | 10 | |||
| 4: T 4 and/or N1 and/or 50 ≤ PSA < 100 µg/L and M0 | 10 | |||
| 4b: PSA ≥ 100 µg/L and M0 | 5 | |||
| 5: Metastasis # | 30 |
* Risk groups were defined according to Gleason score (GS), TNM stage and serum prostate specific antigen (PSA) levels [29]. # Positive scintigraphy or bone scan at diagnosis.